stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Return on equity
Rhythm Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 September 2026 was −167.5%, up 83.6 percentage points from fiscal 2025 (−251.1%). Over the past ten years it has ranged from −276.3% (fiscal 2024) to 142.9% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −251.1% | 25.19 |
| FY2024 | −276.3% | (191.23) |
| FY2023 | −85.1% | (19.05) |
| FY2022 | −66.1% | (35.16) |
| FY2021 | −30.9% | 28.99 |
| FY2020 | −59.9% | (6.50) |
| FY2019 | −53.4% | (15.50) |
| FY2018 | −37.9% | 29.18 |
| FY2017 | −67.1% | (209.92) |
| FY2016 | 142.9% | 83.89 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| CORT Corcept Therapeutics Incorporated compare | 21.7% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| PRAX Praxis Precision Medicines, Inc. compare | −38.9% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −64.9% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| RYTM Rhythm Pharmaceuticals, Inc. | −167.5% |
| AXSM Axsome Therapeutics, Inc. compare | −175.6% |
| ABVX Abivax SA Sponsored ADR compare | −249.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement